Satha Thillaiampalam has been leading various responsibilities within the biopharmaceutical industry. Throughout his twenty-year career as a Biostatistician and Statistical Programmer, he has led numerous strategic initiatives involving cross functional teams to continuously improve systems, processes, and governance. In his current role, he leads the processes and infrastructure activities for oncology biostatistics department within Lilly. His key interests are optimizing operational efficiency and developing high performing systems by leveraging advancements in technology and standards.
Archives: Speakers
Binitha Prasad
Shridhar Munichandrappa
Aroba Hafeez
Bao Dinh
Tony Hung
I started my career at Everest Clinical Research in CDM. I later joined Gilead’s CDM team focusing on infectious disease therapeutic area. I transitioned to commercial (sales analytics) for almost 3 years to better understand the lifecycle of drug post approval. I decided to return to CDM and joined Biomarin to better understand rare diseases. Post Biomarin, I spent some time at Nektar before landing the position at Denali, focusing on rare disease trials again.
Hyunjae Ryan Kim
Dr. Hyunjae Ryan Kim is currently the leader of a team at Gilead Sciences, which specializes in oncology genomics analytics. He is responsible for developing multimodal AI algorithms and applications used in clinical development for oncology. Additionally, he researches how to improve cancer treatment using deep learning and multi-omics data integration by modulating tumor microenvironments.
Dr. Kim previously held the associate director of pediatric oncology bioinformatics position at the Texas Children’s Cancer Center at Baylor College of Medicine (BCM). Before joining BCM, he was a senior computational biologist at the Memorial Sloan Kettering Cancer Center. Dr. Kim and his team developed routine genomic profiling systems (MSK-IMPACT) and matching treatment options for all patients in MSKCC. He also served as research faculty at the Rockefeller University, where he built systems to decipher epigenetic codes and transcriptional controls from multi-omics data with C. David Allis and Thomas Tuschl. Dr. Kim completed his postdoctoral training in Systems Biology at Columbia University Medical Center.
Jonathan Chainey
Jonathan Chainey is an Executive Director and Global Head, Data Standards & Governance within Data Sciences, Product Development at Roche. He leads a global team accountable for the cross-functional governance and adoption of Roche’s CDISC-aligned global data standards across all Roche sponsored early & late phase clinical trials. He is currently serving on CDISC’s board of directors and is chair of CDISC’s Technical Advisory Committee.
Over the past 25 years Jonathan has worked within the biopharmaceutical industry in the U.K., Switzerland, and United States. in a range of disciplines including pre-clinical pharmacological research (Ciba-Geigy), clinical data management (Parexel), statistical programming & analysis (Pfizer, Novartis), applications development (Pfizer, Roche), and process analysis, data standards & governance (Roche).
Jonathan has a scientific background and education including a BSc (Hons) Pharmacology, University of Bath, U.K. He is a British citizen and currently located in the San Francisco Bay Area, California.
Dr. Mark Sullivan
Prior to joining Citrine Informatics as a Senior Solutions Engineer, Dr. Mark Sullivan spent four years with Dow’s Reaction Engineering group within the Core R&D function, where he worked on both experimental and modeling projects that centered around design, scale-up, and optimization of novel catalytic systems. After studying chemical engineering as an undergraduate at the University of Notre Dame, Mark received his PhD studying the fundamentals of transition metal carbide catalyst systems at the University of Minnesota – Twin Cities under the tutelage of Professor Aditya Bhan, and spent two years as a postdoc working with Professor Yuriy Roman studying zeolite catalysis and electrochemical systems.
Scott Palmese
Scott Palmese is currently Executive Director, Decentralized Clinical Trials at Worldwide Clinical Trials. He has been in the clinical research industry for almost 15 years and has held a variety of roles in the site and CRO sectors focusing on operations, business development, and strategic direction. Throughout his career, Scott has consistently been an advocate for sites and patients and is excited about making it easier to access clinical trials across the globe.